United States & European Union — European Medicines Agency
8 shared events · Importance 10 · Last updated Jun 26, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States: The United States is a target for a Biologics License Application (BLA) submission in early 2027 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the country.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
Business
United States: The United States is highlighted as the largest pharmaceutical market globally, making it a key focus for EirGenix's expansion and partnership discussions.
European Union — European Medicines Agency: The European Union — European Medicines Agency is mentioned as a regulatory agency whose harmonized frameworks are streamlining biosimilar approval pathways, benefiting companies like EirGenix.
Jun 30, 2026 · 6 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent for chronic spontaneous urticaria (CSU) in the European Union.
Feb 24, 2026 · 8 articles
NEWSDESK
Explore this relationship live
Track how United States and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.
Open Dashboard